Adaptation and Validation of the Hypomanic Personality Scale (HPS-6) to Romanian
1 other identifier
interventional
50
1 country
1
Brief Summary
The HPS-6 (Hypomanic Personality Scale, 6 item version) could prove to be a valuable candidate for screening measures of high risk individuals. In the following study, we aim to validate and adapt the HPS-6 for the Romanian population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started Sep 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 22, 2025
CompletedFirst Submitted
Initial submission to the registry
January 27, 2026
CompletedFirst Posted
Study publicly available on registry
February 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
ExpectedFebruary 10, 2026
February 1, 2026
7 months
January 27, 2026
February 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (11)
Hypomanic Personality Scale - 6 (HPS-6)
The main instrument of the study, the HPS-6 is used to assess bipolar spectrum disorder risk due to and individual's phenotype. The scale contains 6 items and has a binary rating scale ("TRUE" / "FALSE"). The original authors used a cut-off of 3 or higher to represent possible risk for the disorder. Minimum score possible is 0, while the highest is 6.
Baseline and one month later for re-test measures (in order to account for test-retest reliability)
Mood Disorder Questionnaire (MDQ)
In order to check for convergent validity, the Mood Disorder Questionnaire was administered as well. The instrument screens for a history of manic or hypomanic symptoms. It contains 13 yes or no items created based on the DSM-IV, followed by a 4-point Likert question on the level of impairment; "no problem" to "serious problem" and a 15th item asking is symptoms happened simultaneously. Studies recommend a cut-off of \>5 for high risk bipolar populations. The original cut-off of the scale is \>7, but it has been criticized for high specificity. The total score is 13 (MIN: 0, MAX: 13).
Baseline
Behavioral Inhibition System / Behavioral Activation System scales (BISBAS)
The BIS / BAS scales assess two motivational systems, the Behavioral Inhibition System and the Behavioral Activation System. The scale contains 20 items in total. The BAS system, or the approach tendency, is hypothesized to facilitate goal-motivated behavior when presented with incentives, generating an increase in behaviors oriented towards goals, while the BIS motivational system activates inhibition tendencies. Higher scores indicate sensitivity to threats, non-reward (BIS) or the sensitivity towards reward and goal striving (BAS). Total possible score for the BIS subscale is 28 (MIN: 7, MAX: 28), while for the BAS subscale the total possible is 91 (MIN: 13, MAX: 91).
One month after Baseline
Positive and Negative Affect Schedule (PANAS)
The Positive and Negative Affect Schedule is a 20-item self-report measure assessing positive and negative affect. Participants rate each item on a 5-point Likert scale ranging from 1 ("very slightly or not at all") to 5 ("extremely"). Each subscale has a possible score range of 10 to 50. Higher PA scores reflect greater energy and concentration, whereas higher NA scores indicate greater levels of distress.
One month after Baseline.
Negative Urgency, Premeditation, Perseverance, Sensations Seeking, and Positive Urgency - Impulsive Behavior Scale (UPPS-P)
The UPPS-P Impulsive Behavior Scale assesses positive and negative emotional urgency along with multiple dimensions of impulsivity. The full instrument includes 59 items across five subscales: Negative Urgency, Positive Urgency, (Lack of) Premeditation, (Lack of) Perseverance, and Sensation Seeking. A scoping review has shown that individuals with bipolar disorder exhibit elevated impulsivity during both positive and negative emotional states, with particularly large effect sizes observed for positive urgency. Because the HPS-6 focuses on positively valenced experiences, only the Positive Urgency subscale was administered in this study. Scores on this subscale range from 14 to 56, with higher average scores indicating greater impulsive tendencies.
One month after Baseline
Affective Lability Scale - Short Form (ALS-18)
The ALS-18 is an 18-item measure designed to assess shifts between neutral states and intense affect, emphasizing emotional variability rather than current symptom severity. It comprises three main subscales: Anxiety/Depression Shift (5 items), Depression/Elation Shift (8 items), and Anger (5 items). Items are rated on a 4-point Likert scale ranging from 0 ("very uncharacteristic of me") to 3 ("very characteristic of me"). The total raw score ranges from 0 to 54, with higher scores indicating greater affective lability, reflected in more frequent and intense mood shifts.
One month after Baseline
Positive Overgeneralization (POG)
The Positive Overgeneralization Scale (POG) measures the "tendency to generalize good experiences in one domain to broader aspects of life". it contains 3 subscales (lateral generalization, upward generalization and social generalization), comprising altogether 16 items. Lower scores represent a higher predisposition towards that type of positive overgeneralization (Subscale 1 - Lateral generalization: MAX - 30, MIN: 6 , Subscale 2 - Upward generalization: MAX - 25, MIN - 5, Subscale 3 - Social generalization: MAX - 25, MIN - 5).
One month after Baseline.
Altman Self-Rating Mania Scale (ASRM)
The instrument evaluates manic symptom presence and their severity using 5 items, rated on a 4-point Likert scale. Total scores span from 0 to 20, and scores of 6 or above suggest a possible presence of hypomanic or manic symptoms.
Baseline
Food Neophobia Scale (FNS)
The scale measures one's reluctance to try new or unfamiliar foods. The FNS consists of 10 items rated on a 7-point Likert scale. It has been widely used internationally across diverse fields. Five items assess neophobic behavior, defined as fear of new or unfamiliar experiences, while the remaining five assess neophilic behavior, reflecting interest in and enthusiasm for novelty. Higher FNS scores indicate greater levels of neophobia (MIN: 10, MAX: 70).
Baseline
Patient Health Questionnaire-9 (PHQ-9)
The Patient Health Questionnaire-9 is a diagnostic tool for depression based on DSM-IV criteria. It includes nine items rated on a 4-point Likert scale ranging from 0 ("Not at all") to 3 ("Nearly every day"). Using the algorithm method, a diagnosis is indicated when five or more symptoms have been present for more than half of the days over the past two weeks. Total scores range from 0 to 21. Alternatively, the summed-item approach involves adding the item scores, with a commonly used cutoff of 10 points to indicate major depressive disorder.
Baseline
Importance of Olfaction (IOS)
The Importance of Olfaction scale assesses core olfactory functions. It consists of 18 items rated on a 5-point Likert scale ranging from 1 ("strongly disagree") to 5 ("strongly agree"). The scale was designed for use across different cultures and age groups. It includes five subscales reflecting various domains of the importance of smell (e.g., mating and bonding). Total scores range from 18 to 90, with higher scores indicating a greater personal importance attributed to the sense of smell.
Baseline
Secondary Outcomes (2)
Psychiatric Diagnostic Screening Questionnaire (PDSQ)
Baseline
Suicide Behavior Questionnaire-Revised (SBQ-R)
Baseline
Study Arms (2)
Community Piloting
OTHERMeant for piloting scale, EFA
Clinical / Risk Group
OTHERFormally clinically evaluated sample, used for CFA
Interventions
A brief instrument, such as the HPS-6, with high specificity can help navigate specialists towards a correct diagnosis or recognize risk patterns in Bipolar Spectrum Individuals.
Eligibility Criteria
You may qualify if:
- years of age
- Not at high risk of suicide (current)
- Not high SUDs / AUDs (current)
- Native Romanian speaker
- Cognitive abilities intact (reading comprehension of items)
You may not qualify if:
- High risk of suicide (current)
- High SUDs / AUDs (current)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Babeș-Bolyai University
Cluj-Napoca, 400084, Romania
Related Publications (23)
Wang, H. R., Woo, Y. S., Ahn, H. S., Ahn, I. M., Kim, H. J., & Bahk, W. M. (2015). The validity of the mood disorder questionnaire for screening bipolar disorder: a meta-analysis. Depression and anxiety, 32(7), 527-538. https://doi.org/10.1002/da.22374
BACKGROUNDKroenke, K., Spitzer, R. L., & Williams, J. B. W. (1999). Patient Health Questionnaire-9 (PHQ-9). APA PsycTests, 10. https://doi.org/10.1037/t06165-000
BACKGROUNDManea, L., Gilbody, S., & McMillan, D. (2015). A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. General hospital psychiatry, 37(1), 67-75. https://doi.org/10.1016/j.genhosppsych.2014.09.009
BACKGROUNDLevis, B., Benedetti, A., & Thombs, B. D. (2019). Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. bmj, 365. https://doi.org10.1136/bmj.l1476
BACKGROUNDPliner, P., & Hobden, K. (1992). Development of a scale to measure the trait of food neophobia in humans. Appetite, 19(2), 105-120. https://doi.org/10.1016/0195-6663(92)90014-W
BACKGROUNDRabadán, A., & Bernabéu, R. (2021). A systematic review of studies using the Food Neophobia Scale: Conclusions from thirty years of studies. Food Quality and Preference, 93, 104241. https://doi.org/10.1016/j.foodqual.2021.104241
BACKGROUNDSorokowski, P., Sorokowska, A., Misiak, M., & Roberts, S. C. (2023). Developmental changes in food and non-food odor importance-Data from Scotland and Pakistan. Food Quality and Preference, 111, 104963.
BACKGROUNDMeyer, T. D., & Baur, M. (2009). Positive and negative affect in individuals at high and low risk for bipolar disorders. Journal of Individual Differences, 30(3), 169-175.
BACKGROUNDWatson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.
PMID: 3397865BACKGROUNDTeh, W. L., Si, S. Y., Liu, J., Subramaniam, M., & Ho, R. (2024). The clinical significance of emotional urgency in bipolar disorder: a scoping review. BMC psychology, 12(1), 273.
BACKGROUNDEisner, L. R., Johnson, S. L., & Carver, C. S. (2008). Cognitive responses to failure and success relate uniquely to bipolar depression versus mania. Journal of Abnormal Psychology, 117(1), 154.
BACKGROUNDJohnson, S. L., Turner, R. J., & Iwata, N. (2003). BIS/BAS levels and psychiatric disorder: An epidemiological study. Journal of psychopathology and behavioral assessment, 25(1), 25-36.
BACKGROUNDCarver, C. S., & White, T. L. (1994). Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. Journal of personality and social psychology, 67(2), 319.
BACKGROUNDOsman, A., Bagge, C. L., Gutierrez, P. M., Konick, L. C., Kopper, B. A., & Barrios, F. X. (2001). The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. Assessment, 8(4), 443-454.
BACKGROUNDKwapil, T. R., Miller, M. B., Zinser, M. C., Chapman, L. J., Chapman, J., & Eckblad, M. (2000). A longitudinal study of high scorers on the hypomanic personality scale. Journal of Abnormal Psychology, 109(2), 222. https://doi.org/10.1037/0021-843X.109.2.222
BACKGROUNDSchalet, B. D., Durbin, C. E., & Revelle, W. (2011). Multidimensional structure of the Hypomanic Personality Scale. Psychological assessment, 23(2), 504. https://doi.org/10.1037/a0022301
BACKGROUNDBerson, T. R., Sperry, S. H., Walsh, M. A., & Kwapil, T. R. (2022). A critical examination of multidimensionality within the Hypomanic Personality Scale. Comprehensive Psychiatry, 115, 152306. https://doi.org/10.1016/j.comppsych.2022.152306
BACKGROUNDEckblad, M., & Chapman, L. J. (1986). Development and validation of a scale for hypomanic personality. Journal of abnormal psychology, 95(3), 214. https://doi.org/10.1037//0021-843x.95.3.214
BACKGROUNDMatza, L. S., Rajagopalan, K. S., Thompson, C. L., & De Lissovoy, G. (2005). Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Journal of Clinical Psychiatry, 66(11), 1432-1440. https://doi.org/10.4088/jcp.v66n1114
BACKGROUNDMiller, C. J., Johnson, S. L., Kwapil, T. R., & Carver, C. S. (2011). Three studies on self-report scales to detect bipolar disorder. Journal of affective disorders, 128(3), 199-210. https://doi.org/10.1016/j.jad.2010.07.012
BACKGROUNDZhong, Y., Chen, Y., Su, X., Wang, M., Li, Q., Shao, Z., & Sun, L. (2024). Global, regional and national burdens of bipolar disorders in adolescents and young adults: a trend analysis from 1990 to 2019. General Psychiatry, 37(1), e101255. https://doi.org/10.1136/gpsych-2023-101255
BACKGROUNDIovu, M. B., & Breaz, M. A. (2019). The prevalence and burden of mental and substance use disorders in Romania: Findings from the Global Burden of Disease Study 2016. Psychiatria Danubina, 31(4), 457-464. https://doi.org/10.24869/psyd.2019.457
BACKGROUNDIaru, I., Bucsa, C., Farcas, A., Pop, C., Cristina, A., Armean, S., ... & Mogosan, C. (2023). Utilization of psychotropic medicines in Romania during 1998-2018. Frontiers in Pharmacology, 14, 1157231. https://doi.org/10.3389/fphar.2023.1157231
BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Masking Details
- Clinical Psychologists conducting the clinical interviews are blinded to participant's diagnosis (from intake form), as well as study scales and scope of the study.
- Purpose
- SCREENING
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 27, 2026
First Posted
February 10, 2026
Study Start
September 22, 2025
Primary Completion
May 1, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
February 10, 2026
Record last verified: 2026-02